Penumbra Inc (PEN) Stock Price, Quote & News

Company Profile

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under...

Industry: Medical Devices

Sector: Healthcare

Phone: 510 748 3200

Website: www.penumbrainc.com

Address:

One Penumbra Place, Alameda, United States

RunnerSignals Oct. 20 at 7:30 PM

Analysts going bullish on $AAPL $IRTC $PEN $SONY $KEY today. https://stocksrunner.com/news/2025-10-20-stock-upgrades-today-where-analysts-see-real-money-being-made

0 · Reply

MoneyGroupLLC Oct. 17 at 12:19 PM

Enter: $PEN NOV 21 2025 $260 CALLS Buy in Price: $14.80 - $18.32 Take Profit: $34.26 Stop Bleeding: $16.12 ROI Potential: 87% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

JarvisFlow Oct. 15 at 3:32 PM

Truist Securities has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 300.

0 · Reply

simplejackMD Oct. 11 at 3:52 PM

$PEN I'm unsure if shareholders truly grasp why this company has the reputation it does. When device sales are no longer conducted in person, this company loses its edge. If you buy AI thesis, then you should be thinking and quickly. I'll leave it there. The stock has an aura premium of about $150. Fair value $90. May go up. Do not put in your kids portfolio.

2 · Reply

RunnerSignals Oct. 8 at 8:53 PM

Fresh upgrades today $AFRM $BOKF $FCX $PEN $PFE all catching Wall Street eye. Copper bull case on FCX looking especially strong https://stocksrunner.com/news/2025-10-08-stock-upgrades-today-with-5-promising-opportunities-for-traders

0 · Reply

nikitatrades Oct. 8 at 4:01 PM

$PEN Needham turns bullish on $PEN: 🔄 Upgrades to Buy from Hold, $326 PT. Sees 2026 growth accelerating on Thunderbolt launch, China recovery.

0 · Reply

AStrokeOfLuck Oct. 8 at 3:30 PM

$PEN

0 · Reply

look2theblue Oct. 5 at 10:11 PM

$RVPH $ITRM $PEN All eyes on Monday.

0 · Reply

ZeroDTEHero Oct. 5 at 4:55 PM

$PEN Biotech with clinical catalyst. High short interest. Volatility compression suggests large move imminent. High risk setup.

0 · Reply

MoneyGroupLLC Oct. 4 at 12:08 AM

Enter: $PEN NOV 21 2025 $270 CALLS Buy in Price: $11.04 - $11.50 Take Profit: $19.10 Stop Bleeding: $9.72 ROI Potential: 73% Exit Within: 207 Minutes https://moneygroup.us/alerts

0 · Reply

Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025

Sep 9, 2025, 4:44 PM EDT - 6 weeks ago

Penumbra, Inc. (PEN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 9:00 AM EDT - 6 weeks ago

New Survey Shows Management of Blood Clots is Inconsistent, Even for Patients with the Same Risk Profile

Sep 3, 2025, 12:28 PM EDT - 7 weeks ago

Penumbra, Inc. (PEN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 27, 2025, 9:00 AM EDT - 2 months ago

Penumbra, Inc. Names Shruthi Narayan as Company President

Aug 20, 2025, 4:30 PM EDT - 2 months ago

Penumbra, Inc. to Present at Upcoming Investor Conferences

Aug 7, 2025, 9:45 PM EDT - 2 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

ACLX BSX EW EXAS GH ISRG LLY

Jul 30, 2025, 4:30 PM EDT - 3 months ago

Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 29, 2025, 9:04 PM EDT - 3 months ago

Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:05 PM EDT - 3 months ago

Penumbra, Inc. Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 9:57 AM EDT - 3 months ago

Five years after COVID, pharma shares languish in US policy limbo

ABBV ABT ALNY AZN EW LLY MRK

Jul 1, 2025, 4:30 PM EDT - 4 months ago

Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025

Jun 26, 2025, 6:00 AM EDT - 4 months ago

Penumbra: AI Meets Aspiration - Why The Stock Is A Structural Winner

Jun 16, 2025, 9:00 AM EDT - 4 months ago

Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial

Jun 5, 2025, 9:00 AM EDT - 5 months ago

Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization

Apr 29, 2025, 4:30 PM EDT - 6 months ago

Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

Apr 29, 2025, 11:45 AM EDT - 6 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ACLX ISRG MASI MCK NTRA TMO UNH

Apr 24, 2025, 3:27 PM EDT - 6 months ago

Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst

Apr 23, 2025, 8:15 PM EDT - 6 months ago

Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript

Apr 23, 2025, 4:05 PM EDT - 6 months ago

Penumbra, Inc. Reports First Quarter 2025 Financial Results

Apr 3, 2025, 4:30 PM EDT - 7 months ago

Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025

Apr 2, 2025, 9:00 AM EDT - 7 months ago

Seven New Data Sets Demonstrate Penumbra's Computer Assisted Vacuum Thrombectomy (CAVT) Technology Is Safe, Fast and Effective, Improves Patient Outcomes, and Delivers Healthcare Resource Benefits

Feb 21, 2025, 4:05 PM EST - 8 months ago

Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors

Feb 19, 2025, 4:03 PM EST - 8 months ago

Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook

Feb 18, 2025, 11:04 PM EST - 8 months ago

Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 4:05 PM EST - 8 months ago

Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 21, 2025, 4:30 PM EST - 9 months ago

Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025

Dec 30, 2024, 4:30 PM EST - 10 months ago

Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 11:03 AM EST - 11 months ago

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst

Nov 20, 2024, 4:30 PM EST - 1 year ago

Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:00 AM EST - 1 year ago

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Oct 30, 2024, 11:45 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Third Quarter 2024 Financial Results

Oct 14, 2024, 9:00 AM EDT - 1 year ago

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024

Sep 16, 2024, 3:00 AM EDT - 1 year ago

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Baird Global Healthcare Conference

Aug 21, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference

Aug 19, 2024, 9:28 PM EDT - 1 year ago

Penumbra: Growth In Its Thrombectomy Portfolio Should Lead To Strong Earnings

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Penumbra, Inc. Announces $200 Million Share Repurchase Authorization

Aug 2, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Canaccord Genuity Growth Conference

Jul 30, 2024, 7:25 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q2 2024 Earnings Call Transcript

Jul 30, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Reports Second Quarter 2024 Financial Results

Jul 2, 2024, 4:05 PM EDT - 1 year ago

Penumbra, Inc. Schedules Second Quarter 2024 Earnings Release and Conference Call for July 30, 2024

Jun 21, 2024, 8:22 AM EDT - 1 year ago

Top 3 Health Care Stocks That Could Blast Off In June

ENOV RGEN

Jun 4, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the Truist Securities MedTech Conference

May 23, 2024, 4:30 PM EDT - 1 year ago

Penumbra, Inc. to Present at the William Blair Growth Stock Conference

May 7, 2024, 10:33 PM EDT - 1 year ago

Penumbra, Inc. (PEN) Q1 2024 Earnings Call Transcript

RunnerSignals Oct. 20 at 7:30 PM

Analysts going bullish on $AAPL $IRTC $PEN $SONY $KEY today. https://stocksrunner.com/news/2025-10-20-stock-upgrades-today-where-analysts-see-real-money-being-made

0 · Reply

MoneyGroupLLC Oct. 17 at 12:19 PM

Enter: $PEN NOV 21 2025 $260 CALLS Buy in Price: $14.80 - $18.32 Take Profit: $34.26 Stop Bleeding: $16.12 ROI Potential: 87% Exit Within: 2 Weeks https://moneygroup.us/alerts

0 · Reply

JarvisFlow Oct. 15 at 3:32 PM

Truist Securities has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 300.

0 · Reply

simplejackMD Oct. 11 at 3:52 PM

2 · Reply

RunnerSignals Oct. 8 at 8:53 PM

0 · Reply

nikitatrades Oct. 8 at 4:01 PM

$PEN Needham turns bullish on $PEN: 🔄 Upgrades to Buy from Hold, $326 PT. Sees 2026 growth accelerating on Thunderbolt launch, China recovery.

0 · Reply

AStrokeOfLuck Oct. 8 at 3:30 PM

$PEN

0 · Reply

look2theblue Oct. 5 at 10:11 PM

$RVPH $ITRM $PEN All eyes on Monday.

0 · Reply

ZeroDTEHero Oct. 5 at 4:55 PM

$PEN Biotech with clinical catalyst. High short interest. Volatility compression suggests large move imminent. High risk setup.

0 · Reply

MoneyGroupLLC Oct. 4 at 12:08 AM

Enter: $PEN NOV 21 2025 $270 CALLS Buy in Price: $11.04 - $11.50 Take Profit: $19.10 Stop Bleeding: $9.72 ROI Potential: 73% Exit Within: 207 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 26 at 1:26 AM

Enter: $PEN OCT 17 2025 $260 CALLS Buy in Price: $8.00 - $8.60 Take Profit: $17.89 Stop Bleeding: $7.57 ROI Potential: 108% Exit Within: 280 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 21 at 11:41 AM

Enter: $PEN OCT 17 2025 $260 CALLS Buy in Price: $9.55 - $10.20 Take Profit: $21.68 Stop Bleeding: $8.40 ROI Potential: 127% Exit Within: 371 Minutes https://moneygroup.us/alerts

0 · Reply

MoneyGroupLLC Sep. 19 at 11:19 AM

Enter: $PEN OCT 17 2025 $260 CALLS Buy in Price: $9.55 - $11.10 Take Profit: $16.71 Stop Bleeding: $8.40 ROI Potential: 75% Exit Within: 131 Minutes https://moneygroup.us/alerts

0 · Reply

RunnerSignals Sep. 3 at 3:24 AM

Big upgrade buzz 3/4 $MDT $MS $PEN $PFS $POST all got fresh analyst love today https://stocksrunner.com/news/2025-09-02-stock-upgrades-today-highlight-asns-baba-meta-race-and-more

0 · Reply

JarvisFlow Sep. 2 at 12:00 PM

Evercore ISI Group updates rating for Penumbra ( $PEN ) to Outperform, target set at 300.

0 · Reply

WallStJesus Aug. 28 at 3:11 PM

$PEN UNUSUAL BULL SWEEPER DETECTED

0 · Reply

StockConsultant Aug. 13 at 3:27 AM

A good day for stocks rallying off support with $AMBA $HLT ICLR $M $PEN and $SYF at https://stockconsultant.com/?AMBA

0 · Reply

scientificway Aug. 3 at 4:25 AM

$PEN check MDXG out, up run started today, excelent guidance

0 · Reply

JarvisFlow Jul. 31 at 3:38 PM

Morgan Stanley has updated their rating for Penumbra ( $PEN ) to Equal-Weight with a price target of 266.

0 · Reply

Looking4Bargain Jul. 31 at 7:40 AM

$PEN Always comes through with good earnings. Positioned for acquisition but it's a money maker.

0 · Reply

JarvisFlow Jul. 30 at 3:47 PM

Truist Securities has updated their rating for Penumbra ( $PEN ) to Buy with a price target of 310.

0 · Reply

JarvisFlow Jul. 30 at 2:54 PM

UBS updates rating for Penumbra ( $PEN ) to Buy, target set at 330 → 335.

0 · Reply

Market Cap	9.89B
Revenue (ttm)	1.19B
Net Income (ttm)	14.01M
EPS (ttm)	N/A
PE Ratio	71.80
Forward PE	68.55
Profit Margin	1.17%
Debt to Equity Ratio	0.00

Volume	328,300
Avg Vol	405,104
Day's Range	N/A - N/A
Shares Out	39.00M
Stochastic %K	74%
Beta	0.41
Analysts	Strong Sell
Price Target	$309.41